Maximal exercise capacity

PROCEDURE2 trials

Sponsors

Jean-Luc Balligand, University of Zurich

Conditions

High Altitude Pulmonary HypertensionHypertrophy, Left VentricularMaximal Exercise Capacity

Phase 2

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

CompletedNCT02599480

Jean-Luc BalligandHypertrophy, Left Ventricular

Start: 2016-09-12End: 2022-02-16Updated: 2025-02-10

Unknown Phase

Maximal Exercise Capacity at 2500 m of High Altitude

CompletedNCT05264324

University of ZurichHigh Altitude Pulmonary Hypertension, Maximal Exercise Capacity

Start: 2021-10-20End: 2022-04-15Updated: 2022-05-11

Related Papers

Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction.

2025-03-226 citations

Repurposing the β<sub>3</sub>-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease

JAMA Cardiology2023-09-209 citations